Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA (NWRN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/15/2018 06/18/2018 06/19/2018 06/20/2018 06/21/2018 Date
11.76(c) 11.84(c) 11.88(c) 11.9(c) 11.96 Last
63 181 25 989 29 868 38 133 19 661 Volume
-0.17% +0.68% +0.34% +0.17% +0.50% Change
More quotes
Financials (EUR)
Sales 2018 7,87 M
EBIT 2018 -19,5 M
Net income 2018 -19,4 M
Finance 2018 42,5 M
Yield 2018 -
Sales 2019 18,8 M
EBIT 2019 -22,2 M
Net income 2019 -21,4 M
Finance 2019 16,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 17,9x
EV / Sales2019 8,87x
Capitalization 183 M
More Financials
Company
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for... 
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
06/14NEWRON PHARMACEUTICALS : Provides Update on STARS Clinical Study with Sarizotan ..
AQ
06/13NEWRON PHARMACEUTICALS : Provides Update on STARS Clinical Study with Sarizotan ..
BU
06/13Newron provides update on STARS clinical study with sarizotan for the treatme..
TE
06/13NEWRON PHARMACEUTICALS : provides update on STARS clinical study with sarizotan ..
PU
05/29NEWRON PHARMACEUTICALS : to Present at Jefferies 2018 Healthcare Conference
BU
05/15NEWRON PHARMACEUTICALS : to Present at the UBS Global Healthcare Conference 2018
BU
03/27NEWRON PHARMACEUTICALS : Announces Shareholders Accepted All Motions at the AGM ..
BU
03/27Shareholders accepted all motions at the AGM 2018
TE
03/27NEWRON PHARMACEUTICALS : Shareholders accepted all motions at the AGM 2018
AQ
03/01Newron announces 2017 financial results and provides outlook for 2018
TE
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
05/29Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference  
05/26Critical Survey: Newron Pharmaceuticals $NWPHF versus Dicerna Pharmaceuticals.. 
05/15Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 201.. 
05/15Newron Pharmaceuticals : to Present at the UBS Global Healthcare Conference 2.. 
04/04$NWRN Pharmaceuticals Spa. Newron Pharmaceuticals - 2018 focus on the CNS pi..
1
More tweets
Qtime:29
News from SeekingAlpha
03/01Newron Pharmaceuticals SPA reports FY results 
2017Newron Pharmaceuticals SPA reports 1H results 
2017Newron Pharmaceuticals SPA reports FY results 
2016FDA accepts for review Newron's resubmitted NDA for Xadago; action date March.. 
2016Newron Pharmaceuticals SPA reports 1H results 
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | NWRN | IT0004147952 | 4-Traders
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 24,2 €
Spread / Average Target 134%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA2.41%212
GILEAD SCIENCES-1.97%89 796
VERTEX PHARMACEUTICALS3.44%38 655
REGENERON PHARMACEUTICALS-16.13%33 439
NEUROCRINE BIOSCIENCES, INC.31.87%9 196
GENMAB-6.69%9 076